Press Release August 8, 2017

Fresenius Medical Care to Acquire NxStage Medical in $2 Billion Deal

Alston & Bird’s Food, Drug & Device/FDA Group helped advise Fresenius Medical Care North America in an agreement by Fresenius Medical Care AG & Co., the world’s largest provider of dialysis products and services, to acquire NxStage Medical, Inc., a leading home dialysis device maker. The Alston & Bird team provided assistance with U.S. Food and Drug Administration and related regulatory due diligence as part of the transaction, which is valued at approximately $2 billion.

NxStage produces products aimed at the treatment of end-stage renal disease and acute kidney failure. The company, which is headquartered in Lawrence, MA, and listed on the Nasdaq, posted revenues of $366 million in 2016.

The Alston & Bird regulatory team advising on the transaction was led by partner Julie Tibbets, working closely with associate Justin Mann, senior associate Brendan Carroll, and attorney Caitlin Hosmer.
Media Contact
Alex Wolfe
Communications Director
Phone: 212.210.9442

This website uses cookies to improve functionality and performance. For more information, see our Privacy Statement. Additional details for California consumers can be found here.